244 related articles for article (PubMed ID: 19538050)
1. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Arakawa Y; Mizowaki T; Murata D; Fujimoto K; Kikuchi T; Kunieda T; Takahashi JC; Takagi Y; Miyamoto S
Neurol Med Chir (Tokyo); 2013; 53(11):779-85. PubMed ID: 24140770
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Loss JF; Santos PP; Leone LD; Brunetto AL
Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
7. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553
[TBL] [Abstract][Full Text] [Related]
10. Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: a phase II study.
López-Aguilar E; Sepúlveda-Vildósola AC; Rivera-Márquez H; Cerecedo-Díaz F; Hernández-Contreras I; Ramón-García G; Diegopérez-Ramírez J; Santacruz-Castillo E
Arch Med Res; 2000; 31(2):186-90. PubMed ID: 10880725
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Sanson M; Ameri A; Monjour A; Sahmoud T; Ronchin P; Poisson M; Delattre JY
Eur J Cancer; 1996 Dec; 32A(13):2229-35. PubMed ID: 9038603
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Schäfer N; Tichy J; Thanendrarajan S; Kim Y; Stuplich M; Mack F; Rieger J; Simon M; Scheffler B; Boström J; Steinbach JP; Herrlinger U; Glas M
Oncology; 2011; 80(5-6):330-2. PubMed ID: 21791942
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.
Francesconi AB; Dupre S; Matos M; Martin D; Hughes BG; Wyld DK; Lickliter JD
J Clin Neurosci; 2010 Aug; 17(8):970-4. PubMed ID: 20541421
[TBL] [Abstract][Full Text] [Related]
15. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
16. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Chamberlain MC; Glantz MJ
Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
[TBL] [Abstract][Full Text] [Related]
17. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Kushner BH; Modak S; Kramer K; Basu EM; Roberts SS; Cheung NK
Cancer; 2013 Feb; 119(3):665-71. PubMed ID: 22951749
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
20. Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial.
Oelmann E; Thomas M; Serve H; Kienast J; Zühlsdorf M; Mohr M; Klinke F; Dölken G; Macha H; Schmidt EW; Berdel WE
Oncology; 2002; 63(3):248-53. PubMed ID: 12381904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]